文献速递心力衰竭与心肌病心律失常

老年晚期心衰患者植入ICD的围术期风险与生存分析

Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure.
PubMed 文献 · JAMA Cardiol · 2020-01-01

晚期心衰组30天全因死亡率3.1%,围术期并发症发生率3.74%,均显著高于非晚期心衰对照组。NYHA IV级、缺血性心脏病和糖尿病与死亡风险升高独立相关。

要点

  • 晚期心衰患者ICD/CRT-D围术期并发症率3.74%,显著高于非晚期心衰患者的1.10%。
  • 晚期心衰组30天全因死亡率为3.1%,对照组仅0.5%。
  • NYHA IV级、缺血性心脏病、糖尿病与晚期心衰患者死亡风险升高相关。

核心结论

  • 在接受ICD或CRT-D一级预防的患者中,仅小部分为晚期心衰,但该群体围术期并发症率及30天死亡率显著高于非晚期心衰患者。

研究设计与样本

  • 纳入标准为确诊心衰、左心室射血分数≤35%且有晚期心衰证据(NYHA IV级症状、60天内使用正性肌力药、左心室辅助装置在体或心脏移植等待名单),对照组为NYHA II级且近12个月无心衰住院等条件者。

主要发现

  • 晚期心衰组30天全因死亡率为3.1%(95%CI 2.6%-3.8%),对照组为0.5%(95%CI 0.4%-0.6%),P < .001。
  • 晚期心衰组院内围术期并发症总发生率为3.74%(95%CI 3.12%-4.44%),对照组为1.10%(95%CI 0.95%-1.25%),P < .001。
  • 晚期心衰组主要不良事件为院内死亡(1.82%;95%CI 1.40%-2.34%)和复苏性心脏骤停(1.05%;95%CI 0.73%-1.45%)。
  • NYHA IV级(HR 1.40;95%CI 1.02-1.93;P = .04)、缺血性心脏病(HR 1.24;95%CI 1.04-1.48;P = .02)和糖尿病(HR 1.17;95%CI 1.04-1.33;P = .01)与死亡风险升高相关。

临床怎么用

  • 对晚期心衰患者进行ICD或CRT-D一级预防植入决策时,应充分评估围术期并发症及死亡风险,并与患者及家属沟通。
  • 合并NYHA IV级、缺血性心脏病或糖尿病的晚期心衰患者死亡风险更高,需加强围术期管理。

局限性

  • 本研究为事后分析,可能存在选择偏倚和未测量混杂因素。
  • 研究人群为Medicare按服务收费受益人,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Little is known about the utilization rates and outcomes of implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) placement among patients with advanced heart failure (HF). OBJECTIVE: To examine utilization rates, patient characteristics, and outcomes of ICD and CRT-D placements among patients with advanced HF. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was a post hoc analysis of 81 492 Medicare fee-for-service beneficiaries enrolled in the National Cardiovascular Data Registry ICD Registry between January 2010 and December 2014. Inclusion criteria were patients who had received an HF diagnosis, had a left ventricular ejection fraction of 35% or lower, and showed evidence of advanced HF, which was defined as New York Heart Association (NYHA) class IV symptoms, inotrope use within the last 60 days, left ventricular assist device in situ, or orthotopic heart transplant listing. The comparator group included patients with NYHA class II and no HF hospitalization within the last 12 months, no left ventricular assist device, no orthotopic heart transplant listing, and no current or recent inotrope use. All eligible patients underwent first-time ICD or CRT-D placement for primary prevention of sudden cardiac death. Data were analyzed from January 2010 to December 2014. MAIN OUTCOMES AND MEASURES: All-cause mortality and periprocedural complications. RESULTS: Of 81 492 Medicare patients, 3343 had advanced HF (4.1%) and 19 424 were in the comparator group (23.8%). Among the advanced HF population, the mean (SD) age of patients was 74 (9) years, and patients were predominantly white individuals (81.5%) and men (71.1%). The all-cause mortality rate at 30 days was 3.1% (95% CI, 2.6%-3.8%) in the advanced HF group vs 0.5% (0.4%-0.6%) in the comparator group (P < .001). In the advanced HF population, the aggregate in-hospital periprocedural complication rate was 3.74% (95% CI, 3.12%-4.44%) vs 1.10% (95% CI, 0.95%-1.25%) in the comparator group (P < .001). Most adverse events in this group were in-hospital fatality (1.82%; 95% CI, 1.40%-2.34%) and resuscitated cardiac arrest (1.05%; 95% CI, 0.73%-1.45%). Patients with NYHA class IV (hazard ratio, 1.40; 95% CI, 1.02-1.93; P = .04), ischemic heart disease (hazard ratio, 1.24; 95% CI, 1.04-1.48; P = .02), or diabetes (hazard ratio, 1.17; 95% CI, 1.04-1.33; P = .01) had a higher risk of death. CONCLUSIONS AND RELEVANCE: Among patients undergoing ICD or CRT-D placement for primary prevention of sudden cardiac death, only a small proportion had advanced HF. These patients experienced clinically important periprocedural complication rates associated with in-hospital death and cardiac arrest relative to patients with nonadvanced HF.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Fudim M, Ali-Ahmed F, Parzynski CS, et al. Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. JAMA Cardiol. 2020. PMID: 32211811. doi:10.1001/jamacardio.2020.0391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。